Fremont, Calif-based Myoscience Inc announces that the US Food and Drug Administration has approved the use of the iovera° device, for knee osteoarthritis pain and symptom relief, for up to 90 days.

The non-ipioid and non-systemic iovera° device is engineered to block pain signals from peripheral nerves, according to a media release from Myoscience Inc.

The FDA clearance is the result of an investigation of the device, published in the journal Osteoarthris and Cartilage, that suggested that patients using iovera° reported reduced pain and symptom relief, compared to a sham treatment.

“The addition of osteoarthritis to the indications for the iovera° treatment will help in extending our innovative non-opioid therapy to more patients, especially in the growing baby-boomer population,” says Cary Vance, president and CEO of Myoscience, in the release. “I anticipate this technology to become the non-narcotic and non-systemic solution of choice to manage knee pain.”

[Source(s): Myoscience Inc, PRWeb]